In an interview with CancerNetwork®, Saad Z. Usmani, MD, FACP, hematologist and medical oncologist at Levine Cancer Institute, spoke about the recent approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for use in adult patients with newly diagnosed or relapsed/refractory multiple myeloma.
The addition of this product now allows for subcutaneous dosing of daratumumab.
“One of the concerns that medical oncologists have had is the long infusion time [of daratumumab], especially in the first cycle of treatment,” said Usmani. “The subcutaneous formulation of daratumumab brings a lot of convenience to the patients.”
The combination of daratumumab and hyaluronidase-fihj is now approved for the following indications, of which intravenous daratumumab had already received approval:
- In combination with bortezomib (Velcade), melphalan (Evomela), and prednisone (Rayos)…